These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 32980845)

  • 1. A Real-World, Population-Based Study for the Incidence and Outcomes of Neuroendocrine Neoplasms of Unknown Primary.
    Abdel-Rahman O
    Neuroendocrinology; 2021; 111(9):876-882. PubMed ID: 32980845
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Real-World, Population-Based Study for the Incidence and Outcomes of Neuroendocrine Neoplasms of Nondigestive, Nonpulmonary Primary.
    Abdel-Rahman O; Ghosh S
    Pancreas; 2022 Aug; 51(7):769-773. PubMed ID: 36395402
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changes in Survival Outcomes of Patients With Neuroendocrine Neoplasms Over the Past 15 Years: A Real-World Study.
    Abdel-Rahman O; Pham TM; Pokhrel A; Ruether D; Sawyer MB
    Am J Clin Oncol; 2022 May; 45(5):208-214. PubMed ID: 35383575
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Real-World Study of the Incidence and Outcomes of Early-Onset Well-differentiated Neuroendocrine Neoplasms.
    Abdel-Rahman O; Ghosh S
    Am J Clin Oncol; 2022 Aug; 45(8):338-343. PubMed ID: 35696696
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Temozolomide Alone or Combined with Capecitabine for the Treatment of Metastatic Neuroendocrine Neoplasia: A "Real-World" Data Analysis.
    Bongiovanni A; Liverani C; Foca F; Fausti V; Di Menna G; Mercatali L; De Vita A; Riva N; Calpona S; Miserocchi G; Spadazzi C; Cocchi C; Ibrahim T
    Neuroendocrinology; 2021; 111(9):895-906. PubMed ID: 33221806
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epidemiologic trends and survival of early-onset gastroenteropancreatic neuroendocrine neoplasms.
    Yao H; Hu G; Jiang C; Fan M; Yuan L; Shi H; Lin R
    Front Endocrinol (Lausanne); 2023; 14():1241724. PubMed ID: 37701903
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pattern and risk factors for distant metastases in gastrointestinal neuroendocrine neoplasms: a population-based study.
    Cai W; Tan Y; Ge W; Ding K; Hu H
    Cancer Med; 2018 Jun; 7(6):2699-2709. PubMed ID: 29733523
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinicopathological features and prognosis of gastroenteropancreatic neuroendocrine neoplasms in a Chinese population: a large, retrospective single-centre study.
    Zhang M; Zhao P; Shi X; Zhao A; Zhang L; Zhou L
    BMC Endocr Disord; 2017 Jul; 17(1):39. PubMed ID: 28705205
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of baseline body mass index on the outcomes of patients with neuroendocrine neoplasms.
    Abdel-Rahman O; Ghosh S; Morrish D
    J Endocrinol Invest; 2022 Sep; 45(9):1683-1688. PubMed ID: 35606667
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neuroendocrine tumors of unknown primary site: gold dust or misdiagnosed neoplasms?
    Catena L; Bichisao E; Milione M; Valente M; Platania M; Pusceddu S; Ducceschi M; Zilembo N; Formisano B; Bajetta E
    Tumori; 2011; 97(5):564-7. PubMed ID: 22158484
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of neuroendocrine morphology on cancer outcomes and stage at diagnosis: a UK nationwide cohort study 2013-2015.
    Genus TSE; Bouvier C; Wong KF; Srirajaskanthan R; Rous BA; Talbot DC; Valle JW; Khan M; Pearce N; Elshafie M; Reed NS; Morgan E; Deas A; White C; Huws D; Ramage J
    Br J Cancer; 2019 Nov; 121(11):966-972. PubMed ID: 31649320
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Results of a prospective multicenter neuroendocrine tumor registry reporting on clinicopathologic characteristics of Greek patients.
    Nikou GC; Pazaitou-Panayiotou K; Dimitroulopoulos D; Alexandrakis G; Papakostas P; Vaslamatzis M; Kaldrymidis P; Markussis V; Koumarianou A;
    BMC Endocr Disord; 2016 Feb; 16():8. PubMed ID: 26872616
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcomes of non-metastatic poorly differentiated gastroenteropancreatic neuroendocrine neoplasms treated with surgery: a real-world population-based study.
    Abdel-Rahman O; Rahbari N; Reissfelder C; Oweira H
    Int J Colorectal Dis; 2021 May; 36(5):941-947. PubMed ID: 33145607
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Retrospective Cohort Study of Histology-Proven Neuroendocrine Neoplasms in the Italian Area of Udine.
    Valent F; Tullio A; Kara E; Cipri C; Sciannimanico SM; Vescini F; Grimaldi F
    Endocr Metab Immune Disord Drug Targets; 2021; 21(3):448-457. PubMed ID: 32660412
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor Macroscopic Morphology Is an Important Prognostic Factor in Predicting Chemotherapeutic Efficacy and Clinical Outcomes of Patients With Colorectal Neuroendocrine Neoplasms, One Multicenter Retrospective Cohort Study.
    Wang Z; An K; Li R; Liu Q
    Front Endocrinol (Lausanne); 2021; 12():801741. PubMed ID: 34987482
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incidence trends of lung and gastroenteropancreatic neuroendocrine neoplasms in Switzerland.
    Alwan H; La Rosa S; Andreas Kopp P; Germann S; Maspoli-Conconi M; Sempoux C; Bulliard JL
    Cancer Med; 2020 Dec; 9(24):9454-9461. PubMed ID: 33078908
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epidemiological characteristics of neuroendocrine neoplasms in Beijing: a population-based retrospective study.
    Chi Y; Liu S; Zhang J; Li H; Yang L; Zhang X; Li H; Li Q; Wang N; Lu M; Zhuo M
    BMC Public Health; 2024 May; 24(1):1396. PubMed ID: 38789981
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epidemiological analysis of lung and mediastinal neuroendocrine neoplasms in Japan based on the national database.
    Matsuoka S; Koizumi T; Otsuki K; Tanaka Y; Kanda S; Ide S; Mishima S; Takeda T; Miura K; Eguchi T; Hamanaka K; Shimizu K
    Cancer Epidemiol; 2022 Apr; 77():102116. PubMed ID: 35144127
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Survival in neuroendocrine neoplasms; A report from a large Norwegian population-based study.
    Boyar Cetinkaya R; Aagnes B; Myklebust TÅ; Thiis-Evensen E
    Int J Cancer; 2018 Mar; 142(6):1139-1147. PubMed ID: 29082524
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of primary site, functional status and treatment modality on survival in gastroenteropancreatic neuroendocrine neoplasms with synchronous liver metastasis: a US population-based study.
    Pu N; Habib JR; Bejjani M; Yin H; Nagai M; Chen J; Kinny-Köster B; Chen Q; Zhang J; Yu J; Wu W; Lou W
    Ann Transl Med; 2021 Feb; 9(4):329. PubMed ID: 33708956
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.